Interaction of γ Interferon and 5-Fluorouracil in the H630 Human Colon Carcinoma Cell Line

Cancer Research

Volumn 50, Issue 18, 1990, Pages 5834-5840

  Chu, Edward ^a   Zinn, Sydelle ^a   Boarman, Donna ^a   Allegra, Carmen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GAMMA INTERFERON; RADIOISOTOPE; THYMIDINE; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CULTURE; COLON CARCINOMA; DRUG INTERACTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ADENOCARCINOMA; CELL DIVISION; COLONIC NEOPLASMS; DNA; DRUG INTERACTIONS; DRUG RESISTANCE; FLUORODEOXYURIDYLATE; FLUOROURACIL; FOLIC ACID; HUMAN; INTERFERON TYPE II; RNA; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0025043811     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Pestka, S., Langer, J. A., Zoon, K. C., and Samuel, C. E. Interferons and their actions. Annu. Rev. Biochem., 56: 727–778, 1987.
2. Clark, J. W., and Longo, D. L. Interferons in cancer therapy. Cancer Principles Pract. Oncol. Updates, 7(4): 1–16, 1987.
3. Krown, S. E. Interferons and interferon inducers in cancer treatment. Semin. Oncol., 75: 207–217, 1986.
4. Borden, E. C., and Hawkins, M. J. Biologic response modifiers as adjuncts to other therapeutic modalities. Semin. Oncol., 13: 144–152, 1986.
5. Bonnern, E. M., and Oldham, R. K. Gamma-interferon: physiology and speculation on its role in medicine. J. Biol. Response Modif., 6: 275–301, 1987.
6. Namba, M., Miyoshi, T., Kanamori, T., Nobuhara, M., Kimoto, T., and Ogawa, S. Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Gann, 73: 819–824, 1982.
7. Miyoshi, T., Ogawa, S., Kanamori, T., Nobuhara, M., and Namba, M. Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett., 77: 239–241, 1983.
8. Inoue, M., and Tan, Y. H. Enhancement of actinomycin-D and m-diam-minedichloroplatinum(II)-induced killing of human fibroblasts by human β interferon. Cancer Res., 43: 5484–5488, 1983.
9. Aapro, M. S., Alberts, D. S., and Salmon, S. E. Interaction of human leukocyte interferon with Vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother. Pharmacol., 10: 161–166, 1983.
10. Le, D., Yip, Y. K., and Vilcek, J. Cytolytic activity of interferon-gaµa and its synergism with 5-fluorouracil. Int. J. Cancer, 34: 495–500, 1984.
11. Yamamoto, S., Tanaka, H., Kanamori, T., Nobuhara, M., and Namba, M. In vitro studies of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa). Cancer Lett., 20: 131–138, 1983.
12. Kimoto, Y. Antitumor effect of interferons with chemotherapeutic agents. Can. To Kayaku Ryoho, 13: 293–301, 1986.
13. Gohji, K., Macda, S., Sugiyama, T., Ishigumi, J., and Kamidono, S. Enhanced inhibition of anticancer drugs by human recombinant gamma interferon for human renal cell carcinoma in vitro. J. Urol., 137: 539–543, 1987.
14. Mitchell, M. S. Combining chemotherapy with biological response modifiers in treatment of cancer. J. Natl. Cancer Inst., 80: 1445–1450, 1988.
15. Elias, L., and Crissman, H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res., 48: 4868–4873, 1988.
16. Stolfi, R. L., and Martin, D. S. Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon. J. Biol. Response Modif., 4: 634–639, 1985.
17. Stolfi, R. L., Martin, D. S., Sawyer, R. C., and Spiegelman, S. Modulation of 5-fluorouraciI-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid. Cancer Res., 43: 561–566, 1983.
18. Iigo, M., Chapekar, M. S., and Glazer, R. I. Synergistic antitumor effect of fluoropyrimidines and polyinosinic-polycytidylic acid against LI210 leukemia. Cancer Res., 45: 4039–4042, 1985.
19. Swain, S. M., Lippman, M. E., Egan, E. F., Drake, J. C., Steinberg, S. M., and Allegra, C. J. 5-Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7: 890–899, 1989.
20. Park, J. G., Oie, H. K., Sugarbaker, P. H., Henslee, J. G., Chen, T. R., Johnson, B. E., and Gazdar, A. Characteristics of cell lines established from human colorectal carcinoma. Cancer Res., 47: 6710–6718, 1987.
21. Park, J. G., Kramer, B. S., Steinberg, S. M., Carmichael, J., Collins, J. M., Minna, J. D., and Gazdar, A. F. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res., 47: 5875–5879, 1987.
22. Moran, R. G., Spears, C. P., and Heidelberger, C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridyIate, 2′-deoxyuridylate, and thymidylate synthase. Proc. Natl. Acad. Sci. USA, 76: 1456–1460, 1979.
23. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, J. H. In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinoma. Cancer Res., 42: 450–456, 1982.
24. Allegra, C. J., Chabner, B. A., Drake, J. C., Lutz, R., Rodbard, D., and Jolivet, J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem., 260: 9720–9726, 1985.
25. Chu, M. Y., and Fischer, G. A. Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem. Pharmacol., 14: 333–341, 1965.
26. Chu, M. Y., and Fischer, G. A. Effects of cytosine arabinoside on the cell viability and uptake of deoxypyrimidine nucleosides in L5178Y cells. Biochem. Pharmacol., 17: 741–751, 1968.
27. Harkrader, R. J., Boritzki, T. J., and Jackson, R. C. Potentiation of 1–0-d-arabinofuranosylcytosine in hepatoma cells by 2′-deoxyadenosine or 2′-deoxyguanosine. Biochem. Pharmacol., 30: 1099–1104, 1981.
28. Pogolotti, A. L., Jr., Nolan, P. A., and Santi, D. V. Methods for the complete analysis of 5-fluorouracil metabolites in cell extracts. Anal. Biochem., 117: 178–186, 1981.
29. Grem, J. L., and Fischer, P. H. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluo-rodeoxyuridine monophosphate levels. Cancer Res., 46: 6191–6199, 1986.
30. Moran, R. G., Spears, C. P., and Heidelberger, C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc. Natl. Acad. Sci. USA, 76: 1456–1460, 1979.
31. Allegra, C. J., Fine, R. L., Drake, J. C., and Chabner, B. A. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. J. Biol. Chem., 261: 6478–6485, 1986.
32. Bunni, M., Doig, M. T., Donato, H., Kesavian, V., and Priest, D. G. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells. Cancer Res., 48: 3398–3404, 1988.
33. Drake, J. C., Chabner, B., Weiss, R., and Allegra, C. The measurement of 5–10-methylene tetrahydrofolate (MTHF): a comparison of assays. Proc. Am. Assoc. Cancer Res., 30: 592, 1989.
34. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248–254, 1976.
35. Chabner, B. A. Pyrimidine antagonists. In: B. A. Chabner (ed.), Pharmacologic Principles of Cancer Treatment, pp. 183–212. Philadelphia: W. B. Saunders Co., 1982.
36. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, T. H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluoro-uracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res., 42: 450–456, 1982.
37. Berne, M. H. O., Gustavsson, B. G., Almersjo, O., Spears, P. C., and Frosing, R. Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma. Cancer Chemother. Pharmacol., 16: 237–242, 1986.
38. Washtien, W. L. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol. Pharmacol., 25: 171–177, 1984.
39. Berne, M., Gustavsson, B., Almersjo, O., Spears, C. P., and Waldenstrom, J. Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2′-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver. Cancer Chemother. Pharmacol., 20: 193–197, 1987.
40. Keyomarsi, K., and Moran, R. G. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J. Biol. Chem., 263: 14402–14409, 1988.
41. Schuetz, J. O., Gorse, K. M., Goldman, I. D., and Westin, E. H. Transient inhibition of DNA synthesis by 5-fluorodeoxyuridine leads to overexpression of dihydrofolate reductase with increased frequency of methotrexate resistance. J. Biol. Chem., 263: 7708–7712, 1988.
42. Friedman, R. L., and Stark, G. R. αInterferon-induced transcription of HCA and metallothionein genes containing homologous upstream sequences. Nature (Lond.), 314: 637–639, 1985.
43. Czaja, M. J., Weinser, F. R., Eghbali, M., Giambrone, M. A., Eghbali, M., and Zero, M. A. Differential effects of 7-interferon on collagen and fibro-nectin gene expression. J. Biol. Chem., 262: 13348–13351, 1987.
44. Knight, E., Anton, E. O., Fahey, O., Friedland, B. K., and Jonak, G. J. Interferon regulated c-myc gene expression in Daudi cells at the posttran-scriptional level. Proc. Natl. Acad. Sci. USA, 82: 1151–1154, 1985.